Home Cart Sign in  
Chemical Structure| 146464-95-1 Chemical Structure| 146464-95-1

Structure of Pralatrexate
CAS No.: 146464-95-1

Chemical Structure| 146464-95-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pralatrexate is an antifolate, and structurally a folate analog. Its IC50 is < 300 nM in some cell lines.

Synonyms: NSC 754230; 10-Propargyl-10-deazaaminopterin; PDX

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pralatrexate

CAS No. :146464-95-1
Formula : C23H23N7O5
M.W : 477.47
SMILES Code : O=C(O)[C@@H](NC(C1=CC=C(C(CC#C)CC2=NC3=C(N)N=C(N)N=C3N=C2)C=C1)=O)CCC(O)=O
Synonyms :
NSC 754230; 10-Propargyl-10-deazaaminopterin; PDX
MDL No. :MFCD00920897
InChI Key :OGSBUKJUDHAQEA-WMCAAGNKSA-N
Pubchem ID :148121

Safety of Pralatrexate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H361
Precautionary Statements:P201-P202-P264-P270-P280-P301+P310+P330-P308+P313-P405-P501

Isoform Comparison

Biological Activity

Target
  • DHFR

In Vitro:

Cell Line
Concentration Treated Time Description References
Hut-78 2.8 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on T-cell lymphoma, IC50 of 2.8 nM PMC7581941
Karpas-299 24.7 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on T-cell lymphoma, IC50 of 24.7 nM PMC7581941
Jeko-1 18.7 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on B-cell lymphoma, IC50 of 18.7 nM PMC7581941
SUDHL-5 5.5 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on B-cell lymphoma, IC50 of 5.5 nM PMC7581941
SUDHL-4 5.6 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on B-cell lymphoma, IC50 of 5.6 nM PMC7581941
HT 7.4 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on B-cell lymphoma, IC50 of 7.4 nM PMC7581941
CCRF-CEM 2.6 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on T-cell leukemia, IC50 of 2.6 nM PMC7581941
Hut-78 2.8 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on Hut-78 cells, IC50 was 2.8 nM PMC7581941
Karpas-299 24.7 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on Karpas-299 cells, IC50 was 24.7 nM PMC7581941
Jeko-1 18.7 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on Jeko-1 cells, IC50 was 18.7 nM PMC7581941
HT 7.4 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on HT cells, IC50 was 7.4 nM PMC7581941
SUDHL-5 5.5 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on SUDHL-5 cells, IC50 was 5.5 nM PMC7581941
SUDHL-4 5.6 nM (IC50) 72 hours Evaluate the growth inhibitory effect of PLX on SUDHL-4 cells, IC50 was 5.6 nM PMC7581941
HPNE 5.46 ± 1.48 nM (IC50) 72 hours Pralatrexate had a weaker inhibitory effect on HPNE cells. PMC9761725
BxPC-3 2.38 ± 0.15 nM (IC50) 72 hours Pralatrexate significantly inhibited the growth of BxPC-3 cells. PMC9761725
BxPC-GEM-20 3.43 ± 0.25 nM (IC50) 72 hours Pralatrexate significantly inhibited the growth of BxPC-GEM-20 cells and effectively inhibited their clonal formation. PMC9761725
HPNE 5.46 ± 1.48 nM (IC50) 72 hours Evaluate the inhibitory effect of Pralatrexate on HPNE cells, results showed Pralatrexate significantly inhibited cell growth PMC9761725
BxPC-3 2.38 ± 0.15 nM (IC50) 72 hours Evaluate the inhibitory effect of Pralatrexate on BxPC-3 cells, results showed Pralatrexate significantly inhibited cell growth PMC9761725
BxPC-GEM-20 3.43 ± 0.25 nM (IC50) 72 hours Evaluate the inhibitory effect of Pralatrexate on BxPC-GEM-20 cells, results showed Pralatrexate significantly inhibited cell growth PMC9761725

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice BxPC-GEM-20 xenograft model Intravenous injection 20 mg/kg Twice a week for 3 weeks Pralatrexate significantly inhibited tumor growth with an inhibitory rate of 76.92%, and had little effect on liver and kidney function as well as body weight changes. PMC9761725
Nude mice BxPC-GEM-20 xenograft model Intravenous injection 20 mg/kg Twice a week for 3 weeks Evaluate the inhibitory effect of Pralatrexate on BxPC-GEM-20 xenograft tumors, results showed Pralatrexate significantly inhibited tumor growth with an inhibition rate of 76.92% PMC9761725

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01626664 Adult T-cell Leukemia-Lymphoma Phase 2 Completed - United States, California ... More >> Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Florida University of Miami / Sylvester Comprehensive Cancer Center Miami, Florida, United States, 33136 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Maryland National Cancer Institute Bethesda, Maryland, United States, 20892 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 Memorial Sloan Kettering New York, New York, United States, 10021 Columbia Presbyterian New York, New York, United States, 10032 Weill Cornell Medical College New York, New York, United States, 10065 Belgium Cliniques Universitaires Saint-Luc Bruxelles, Belgium, 1200 Brazil Hospital Universitario Professor Edgard Santos- UFBA Salvador, Bahia, Brazil, 40110-060 Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Sao Paulo- SP, Brazil, CEP 05403-000 France CHU de Fort de France Fort De France Cedex, France, BP 632 97261 Hospital Necker Paris, France, 75743 Peru Hospital Nacional Edgardo Rebagliati Martins Lima, Peru, Lima11 Instituto Oncologico Miraflores Lima, Peru, Lima18 United Kingdom Guy's Hospital London, United Kingdom, SE1 9RT Imperial College London, United Kingdom, W2 1PG Sandwell General Hospital West Midlands, United Kingdom, B71 4HJ Less <<
NCT01626664 - Completed - -
NCT01482962 - Completed - -
NCT01482962 Relapsed Peripheral T-Cell Lym... More >>phoma Refractory Peripheral T-Cell Lymphoma Less << Phase 3 Completed - -
NCT02551718 Acute Leukemia of Ambiguous Li... More >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia Less << Not Applicable Recruiting - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker    206-616-1589    pbecker@u.washington.edu    Principal Investigator: Pamela S. Becker Less <<
NCT03719105 NK-Cell Lymphoma ... More >> NK-Cell Leukemia Peripheral T Cell Lymphoma Less << Early Phase 1 Not yet recruiting December 31, 2023 -
NCT01206465 - Completed - -
NCT00024245 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT01206465 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Nebraska ... More >> UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-6805 Less <<
NCT00052442 Lymphoma Phase 2 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT00004238 Lung Cancer Phase 2 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT00722553 Carcinoma, Transitional Cell ... More >> Bladder Cancer Bladder Neoplasm Less << Phase 2 Completed - United States, Arizona ... More >> The University of Arizona Health Sciences Center Tucson, Arizona, United States, 85724 United States, Georgia Peachtree Hematology/Oncology Consultants Atlanta, Georgia, United States, 30318 United States, New York University of Rochester Cancer Center Rochester, New York, United States, 14642 United States, Utah University of Utah, Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Argentina Centro de Terapia Radiante Cumbres (CAICI) Rosario, Santa Fe, Argentina, 2000 IONC (Instituto Oncológuci de Cordoba) Cordoba, Argentina, X5004BAL Belgium Algemeen Ziekenhuis Middelheim Antwerp, Belgium, 2020 Institut Jules Bordet Brussels, Belgium, 1000 Croatia CH Split Clinic of Oncology and Radiotherapy Split, Croatia, 21000 CHU Zagreb University Hospital Center Rebro in Zagreb Zagreb, Croatia, 10000 Clinic of Oncology and Nuclear Medicine, CH "Sestre Milosrdnice" Zagreb, Croatia, 10000 France Institut Sainte Catherine Avignon, France, 84082 Centre Oscar Lambret Lille Cedex, France, 59020 Centre Hospitalier Rene Dubos Pontoise, France, 95301 Hopital Foch Suresnes, France Institut Gustave Roussy Villejuif Cedex, France, 94 805 Spain Ciutat Sanitari de Vall d'Hebron Barcelona, Spain, 08035 Hospital Del Mar - Barcelona Barcelona, Spain, 8003 Hospital Virgen del Rocio Sevilla, Spain, 41013 Less <<
NCT00722553 - Completed - -
NCT01129206 - Completed - -
NCT01129206 Adenocarcinoma of the Esophagu... More >>s Adenocarcinomas of the Gastroesophageal Junction Recurrent Esophageal Cancer Squamous Cell Carcinoma of the Esophagus Stage IV Esophageal Cancer Less << Phase 2 Completed - United States, Ohio ... More >> Ohio State University Columbus, Ohio, United States, 43210 Less <<
NCT00481871 Relapsed or Refractory Lymphop... More >>roliferative Malignancies Hodgkin's Lymphoma Peripheral T-cell Lymphoma B-cell Lymphoma Waldenstrom's Macroglobulinemia Less << Phase 1 Phase 2 Completed - United States, California ... More >> University of California at Los Angeles Los Angeles, California, United States, 90095-7077 Stanford University School of Medicine Stanford, California, United States, 94305 United States, Colorado Rocky Mountain Cancer Center Denver, Colorado, United States, 80218 United States, Illinois University of Chicago Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115-6013 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 United States, New Jersey The Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York New York University Hospital New York, New York, United States, 10016 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10017 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Cancer Therapy & Research Center San Antonio, Texas, United States, 78229-4427 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 Less <<
NCT00998946 Lymphoma, B-Cell Phase 2 Completed - United States, California ... More >> Tower Cancer Research Foundation Beverly Hills, California, United States, 90211 United States, Idaho Kootenai Cancer Center Post Falls, Idaho, United States, 83854 United States, Illinois Rush University Medical Center Chicago, Illinois, United States, 60612 United States, Kentucky Owsley Brown Frazier Cancer Center Louisville, Kentucky, United States, 40245 United States, Louisiana Overton Brooks VA Medical Center Shreveport, Louisiana, United States, 71101 United States, Montana Frontier Cancer Center and Blood Institute Billings, Montana, United States, 59102 United States, New York New York University Hospital New York, New York, United States, 10016 United States, Oregon Providence Cancer Center Portland, Oregon, United States, 97225 United States, Tennessee The West Clinic (ACORN) Memphis, Tennessee, United States, 38120 United States, Wisconsin Gundersen Lutheran LaCrosse, Wisconsin, United States, 54601 University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53705-2275 Less <<
NCT02013362 Peripheral T-cell Lymphoma Phase 1 Phase 2 Completed - Japan ... More >> National Hospital Organization Nagoya Medical Center Nagoya, Aichi, Japan, 460-0001 National Cancer Center Hospital Chuo, Tokyo, Japan, 104-0045 Okayama University Hospital Okayama,, Japan, 700-8558 Less <<
NCT00481871 - Completed - -
NCT01336933 - Completed - -
NCT01134341 Cutaneous T-cell Lymphoma ... More >> Mycosis Fungoides Sezary Syndrome Primary Cutaneous Anaplastic Large Cell Lymphoma Less << Phase 1 Completed - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, Pennsylvania University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, United States, 15213 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Italy Ospedale Sant'Orsola - Policlinico Sant'Orsola Bologna, Italy, 40138 Less <<
NCT01336933 Anaplastic Large Cell Lymphoma... More >> Angioimmunoblastic T-cell Lymphoma Hepatosplenic T-cell Lymphoma Peripheral T-cell Lymphoma Less << Phase 2 Completed - United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, California Stanford University Stanford, California, United States, 94305 United States, Georgia Emory University School Of Medicine Atlanta, Georgia, United States, 30308 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Massachusetts University of Massachusetts Medical School Worcester, Massachusetts, United States, 01655 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Siteman Cancer Center at Washington University Saint Louis, Missouri, United States, 63110 United States, Nebraska UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-6805 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 Less <<
NCT01118624 Breast Cancer ... More >> Breast Tumors Neoplasms, Breast Cancer of the Breast Human Mammary Carcinoma Less << Phase 2 Completed - United States, Oregon ... More >> Providence Cancer Center Portland, Oregon, United States, 97213 United States, Tennessee The West Clinic Memphis, Tennessee, United States, 38120 Czech Republic Fakultní nemocnice Olomouc Olomouc, Czech Republic, 775 20 Multiscan, s.r.o. Pardubice, Czech Republic, 532 03 Fakultní nemocnice Královské Vinohrady - FNKV Praha, Czech Republic, 100 34 France Centre Lutte Contre le Cancer Val d'Aurelle (CRLC) Montpellier, Cedex 5, France, 34298 Centre Régional de Lutte Contre le Cancer Alexis Vautrin Vandoeuvre, les Nancy Cedex, France, 54511 Centre Georges François Leclerc Dijon Cedex, France, 21079 Centre Léon Bérard Lyon Cedex, France, 69373 Institut Paoli Calmettes Marseille, France, 13273 Institut Jean-Godinot Reims Cedex 09, France, 51056 Hungary University of Debrecen Medical and Health Science Center Debrecen, Hajdú-Bihar, Hungary, 4032 Semmelweis University Budapest Budapest, Hungary, H-1082 National Health Centre of Hungary Budapest, Hungary, H-1145 Less <<
NCT01118624 - Completed - -
NCT03356678 Relapsed or Refractory Periphe... More >>ral T-cell Lymphoma Less << COMPLETED 2017-06-30 Samsung Medical Center, Seoul,... More >> Seoul, Korea, Republic Of, 135-710, Korea, Republic of|81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, 06351, Korea, Republic of Less <<
NCT00364923 Peripheral T-cell Lymphoma Phase 2 Completed - -
NCT03161223 Lymphoma, T-Cell Phase 1 Phase 2 Recruiting June 30, 2020 United States, New York ... More >> Center for Lymphoid Malignancies at CUMC Recruiting New York, New York, United States, 10019 Contact: Michelle Malanga, MPA          Principal Investigator: Owen A O'Connor, M.D., PhD          Sub-Investigator: Jennifer E Amengual, M.D.          Sub-Investigator: Ahmed Sawas, M.D.          Sub-Investigator: Changchun Deng, M.D.          Sub-Investigator: Lorenzo Falchi, M.D.          Italy University of Bologna Not yet recruiting Bologna, Italy Principal Investigator: Pier Luigi Zinzani, M.D., PhD.          Korea, Republic of Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of Principal Investigator: Won Seog Kim, M.D., Ph.D. Less <<
NCT01820091 Non-Small Cell Lung Cancer Phase 1 Withdrawn April 2015 -
NCT00364923 - Completed - -
NCT00554827 Cutaneous T-cell Lymphoma Phase 1 Completed - United States, California ... More >> City of Hope National Medical Center Duarte, California, United States, 91010 Stanford University School of Medicine Redwood City, California, United States, 94063 United States, Connecticut Yale University School of Medicine New Haven, Connecticut, United States, 06519 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10017 Columbia University Medical Center New York, New York, United States, 10032 United States, Texas University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77080-4009 United States, Washington Fred Hutchinson Cancer Center Seattle, Washington, United States, 98109 Less <<
NCT01188876 - Completed - -
NCT01789723 Non Hodgkin's Lymphoma Phase 1 Withdrawn March 2015 -
NCT00606502 Non-small Cell Lung Cancer Phase 2 Completed - -
NCT01183065 Head and Neck Cancer Phase 2 Completed - United States, New Jersey ... More >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan-Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan-Kettering at Mercy Medical Center Rockville Centre, New York, United States Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital Sleepy Hollow, New York, United States Less <<
NCT01183065 - Completed - -
NCT03240211 PTCL CTCL Phase 1 Recruiting December 2020 United States, New York ... More >> 51 West 51st Street, Suite 200 Recruiting New York, New York, United States, 10019 Contact: Michelle Malanga    212-326-5731    mm4629@cumc.columbia.edu    Italy University of Bologna Not yet recruiting Bologna, Italy Principal Investigator: Pier Luigi Zinzani, MD, PhD          Korea, Republic of Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of Principal Investigator: Won Seog Kim, MD, PhD Less <<
NCT01178944 Adenocarcinoma of the Gastroes... More >>ophageal Junction Esophageal Undifferentiated Carcinoma Gastric Adenocarcinoma Gastric Squamous Cell Carcinoma Recurrent Esophageal Adenocarcinoma Recurrent Esophageal Squamous Cell Carcinoma Recurrent Gastric Carcinoma Stage IIIB Esophageal Adenocarcinoma Stage IIIB Esophageal Squamous Cell Carcinoma Stage IIIB Gastric Cancer Stage IIIC Esophageal Adenocarcinoma Stage IIIC Esophageal Squamous Cell Carcinoma Stage IIIC Gastric Cancer Stage IV Esophageal Adenocarcinoma Stage IV Esophageal Squamous Cell Carcinoma Stage IV Gastric Cancer Undifferentiated Gastric Carcinoma Less << Phase 2 Completed - United States, New York ... More >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Rochester General Hospital Rochester, New York, United States, 14621 Less <<
NCT01114282 Multiple Myeloma Phase 1 Completed - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Less <<
NCT02106650 Relapsed Peripheral T-Cell Lym... More >>phoma Refractory Peripheral T-Cell Lymphoma Less << Phase 2 Recruiting December 2018 United States, Kansas ... More >> Cancer Center of Kansas Recruiting Wichita, Kansas, United States, 67214 Contact: Shaker Dakhil          Principal Investigator: Shaker Dakhil, MD          United States, Washington Seattle Cancer Care Alliance Recruiting Seattle, Washington, United States, 98109 Contact: Andrei Shustov          Principal Investigator: Andrei Shustov, MD Less <<
NCT01178944 - Completed - -
NCT01420679 Peripheral T-cell Lymphoma Phase 3 Terminated - -
NCT03598998 Recurrent Mature T- and NK-Cel... More >>l Non-Hodgkin Lymphoma Recurrent Mycosis Fungoides Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Refractory Mycosis Fungoides Less << Phase 1 Phase 2 Not yet recruiting April 27, 2021 United States, California ... More >> City of Hope Medical Center Not yet recruiting Duarte, California, United States, 91010 Contact: Alex F. Herrera, MD    626-256-4673 ext 62405    aherrera@coh.org    Principal Investigator: Alex F. Herrera, MD          United States, Nebraska University of Nebraska Medical Center Not yet recruiting Omaha, Nebraska, United States, 68198 Contact: Matthew A. Lunning, MD    402-559-3848    mlunning@unmc.edu    Principal Investigator: Matthew A. Lunning, MD          United States, New Jersey Hackensack University Medical Center Not yet recruiting Hackensack, New Jersey, United States, 07601 Contact: Tatyana A. Feldman, MD    551-996-4469    Tatyana.Feldman@Hackensackmeridian.org    Principal Investigator: Tatyana A. Feldman, MD Less <<
NCT03349333 Refractory Peripheral T-Cell L... More >>ymphoma Relapsed T-Cell Lymphoma Less << Phase 3 Active, not recruiting March 30, 2019 China ... More >> Beijing Cancer Hospital Beijing, China, 100142 Less <<
NCT01947140 Lymphoid Malignancies ... More >> Multiple Myeloma Lymphoma Hodgkin Lymphoma Non-hodgkin Lymphoma Less << Phase 1 Phase 2 Recruiting December 2018 United States, New York ... More >> Columbia University Medical Center Recruiting New York, New York, United States, 10019 Contact: Renee Lichtenstein    212-326-5720    rl2619@cumc.columbia.edu    Principal Investigator: Jennifer E Amengual, MD Less <<
NCT03355768 Lymphoma, T-Cell, Peripheral Phase 3 Not yet recruiting January 2020 United States, New York ... More >> Center for Lymphoid Malignancies at CUMC Not yet recruiting New York, New York, United States, 10019 Contact: Michelle Malanga, MPA    212-326-5731    mm4629@cumc.columbia.edu Less <<
NCT00606502 - Completed - -
NCT02594267 Peripheral T-Cell Lymphoma (PT... More >>CL) Less << Phase 1 Recruiting December 2018 United States, Washington ... More >> Seattle Cancer Care Alliance/University of Washington Recruiting Seattle, Washington, United States, 98109 Contact: Andrei Shustov, MD          Principal Investigator: Andrei Shustov, MD Less <<
NCT01188876 Ovarian Cancer ... More >> Fallopian Tube Cancer Peritoneal Cancer Less << Phase 1 Phase 2 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT01532011 Advanced Cancers ... More >> Solid Tumors Less << Phase 1 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03150602 Peripheral T Cell Lymphoma|Pro... More >>gression, Disease Less << PHASE4 UNKNOWN 2020-12-31 Ntional Taiwan University Hosp... More >>ital, Taipei, 100, Taiwan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.47mL

2.09mL

1.05mL

20.94mL

4.19mL

2.09mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories